Fatigue is the most common symptom related to cytotoxic chemotherapeutic treatment of cancer. Peripheral inflammation associated with cytotoxic chemotherapy is likely a causal factor of fatigue. The neural mechanisms by which cytotoxic chemotherapy associated inflammation induces fatigue behavior are not known. This lack of knowledge hinders development of interventions to reduce or prevent this disabling symptom. Infection induced fatigue/lethargy in rodents is mediated by suppression of hypothalamic orexin activity. Orexin is critical for maintaining wakefulness and motivated behavior. Though there are differences between infection and cytotoxic chemotherapy in some symptoms, both induce peripheral inflammation and fatigue. Based on these similarities we hypothesized that cytotoxic chemotherapy induces fatigue by disrupting orexin neuron activity. We found that a single dose of a cytotoxic chemotherapy cocktail (cyclophosphamide, adriamycin, 5-fluorouracil -CAF) induced fatigue/lethargy in mice and rats as evidenced by a significant decline in voluntary locomotor activity measured by telemetry. CAF induced inflammatory gene expression -IL-1R1 (p < 0.001), IL-6 (p < 0.01), TNFa (p < 0.01), and MCP-1 (p < 0.05) -in the rodent hypothalamus 6-24 h after treatment during maximum fatigue/lethargy. CAF decreased orexin neuron activity as reflected by decreased nuclear cFos localization in orexin neurons 24 h after treatment (p < 0.05) and by decreased orexin-A in cerebrospinal fluid 16 h after treatment (p < 0.001). Most importantly, we found that central administration of1 lg orexin-A restored activity in CAF-treated rats (p < 0.05). These results demonstrate that cytotoxic chemotherapy induces hypothalamic inflammation and that suppression of hypothalamic orexin neuron activity has a causal role in cytotoxic chemotherapy-induced fatigue in rodents.
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Introduction
Fatigue is the most common symptom with cytotoxic chemotherapeutic treatment for cancer (Reilly et al., 2013; Shi et al., 2011) . Acute fatigue usually occurs after each dose of chemotherapy (de Jong et al., 2004; Schwartz et al., 2000) and it frequently persists weeks, months, or years after chemotherapy treatment is completed (Berger et al., 2012) . Fatigue negatively impacts physical and social function, return to work, and quality of life (Curt et al., 2000; Shi et al., 2011; Spelten et al., 2003) .
It is not known how cytotoxic chemotherapy causes fatigue. There is increasing evidence that chemotherapy-induced inflammation is an underlying causal mechanism (Bower and Lamkin, 2013; Cleeland et al., 2003; Dantzer et al., 2012; Ryan et al., 2007; Saligan and Kim, 2012; Wood and Weymann, 2013) . Cytotoxic chemotherapy induces inflammatory cytokine production in macrophages in vitro and when administered to rodents (Elsea et al., 2008; Sauter et al., 2011; Wong et al., 2012; Wood et al., 2006) . In clinical studies, elevated blood levels of IL-6 correlate with fatigue in cancer patients exposed to cytotoxic chemotherapy (Liu et al., 2012; Schubert et al., 2007) . In addition, treatment for malignant melanoma with the cytokine interferon-a induces fatigue that is not responsive to antidepressant therapy (Capuron et al., 2002) . The mechanisms by which chemotherapy-induced peripheral inflammation affects neural signaling to cause fatigue behavior are not understood. Our laboratory recently reported that inflammation-induced fatigue from lipopolysaccharide (LPS) administration was associated with reduced hypothalamic orexin neuron activity (Grossberg et al., 2011) . Orexin neuron signaling promotes arousal and wakefulness (Anaclet et al., 2009; Carter et al., 2013; Kantor et al., 2013; Saper et al., 2005) . Since cytotoxic chemotherapy is similar to LPS treatment in that they both induce peripheral inflammation and fatigue, the purpose of this study was to test our hypothesis that cytotoxic chemotherapy induces fatigue by disrupting orexin neuron activity. Since LPS treatment induces hypothalamic inflammatory cytokine expression, a second purpose of this study was to determine if cytotoxic chemotherapy induces inflammatory cytokine expression in the hypothalamus.
